Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| GLOBAL GEOPH | GGS | 7.79% |
| STAAR SURGIC | STAA | 6.23% |
| KAPSTONE PAP | KS | 6.14% |
| HORNBECK OFF | HOS | 5.99% |
| ANIKA THERAP | ANIK | 5.55% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We have lowered our long-term recommendation on Xerox Corporation (XRX - Analyst Report) to Underperform from Neutral due to the lackluster performance of the company’s Technology business. With the sluggish economy still recovering, Xerox may face more headwinds going forward.
Advancements in information technology have replaced traditional means of sending and storing information by digital media. As a result, Xerox and other document industry firms are bearing the brunt of a slowdown in demand for paper-related systems and products.
Xerox also faces stiff competition from other players in the industry such as Canon, Inc. (CAJ - Snapshot Report), Hewlett-Packard Company (HPQ - Analyst Report) and Lexmark International Inc. (LXK - Analyst Report). Moreover, they are broadening their product portfolio and global presence in almost the same way as Xerox.
Xerox posted mixed results in the second quarter of 2012, with adjusted earnings of 26 cents a share which was in line with the Zacks Consensus Estimates but lower than the year-ago quarter by a penny. Revenues declined 1% (up 1% in constant currency) year over year to $5.54 billion, missing the Zacks Consensus Estimate of $5.58 billion.
The company anticipates that the economic downturn will further take a toll on its businesses and has subsequently lowered its full-year earnings outlook. Xerox now expects adjusted earnings between $1.07 and $1.12 per share, down from its earlier projection of $1.12 to $1.18.
However, Xerox is making positive moves in its government healthcare, financial services and retail, travel and insurance businesses. In addition, new partner print services offerings and new signings were other positive takeaways from the recently reported quarter.
However, we believe that economic weakness in Europe and intense competition from its peers might affect the company’s operations. We are also concerned about its rising debt level, which stood at $9.2 billion as of June 30, 2012, compared with $8.6 billion as of December 31, 2011.
Our long-term Underperform recommendation on Xerox is backed by a Zacks #4 Rank, reflecting a short-term (1 to 3 months) Sell rating.
Get the full Analyst Report on XRX - FREE
Get the full Analyst Report on LXK - FREE
Get the full Analyst Report on HPQ - FREE
Get the full Snapshot Report on CAJ - FREE